QL1706 As Second-line Treatment in Patients with Advanced Hepatocellular Carcinoma
Status:
NOT_YET_RECRUITING
Trial end date:
2026-08-01
Target enrollment:
Participant gender:
Summary
This is a phase I trial to assess the safety and preliminary efficacy of QL1706 in Treating Advanced Hepatocellular Carcinoma Patients refractory to prior immunotherapy.